Novanta Announces Financial Results for the Third Quarter 2026

Novanta Inc. (NOVT) reported Q3 2026 revenue of $305M, up 23%, and adjusted EBITDA of $80M, up 38%. GAAP net income was $2M, while adjusted diluted EPS rose 21% to $1.05. The company expects full-year revenue of $1.135B-$1.14B, up 16%, and adjusted EBITDA of $274M-$277M.

Original reporting

standard-freeholder.com

Published Nov 9, 2026, 9:49 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 10:20 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

Source · standard-freeholder.com

Decision brief

The 30-second read

$NOVTBullishHigh

Why it matters

The earnings beat and raised guidance suggest stronger demand and successful recent acquisition, supporting a bullish outlook.

Market read

First‑report earnings release with material beat and upgraded outlook; likely to move the stock and influence related med‑tech peers.

What to watch

Foreign‑currency headwinds and potential post‑acquisition synergies are not fully quantified.

Relevance 8/10Novelty 8/10Timing: today, with conference call tomorrow

Background

Novanta is a technology partner to medical and advanced equipment manufacturers, listed on Nasdaq.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$NOVTBullishHigh confidence

Context

Novanta reported Q3 2026 results with 23% revenue growth, $2M GAAP net income and raised full‑year guidance.

Expected impact

likely upward pressure as investors price in higher revenue and EBITDA outlook

Evidence & confidence

Revenue and adjusted EBITDA beat expectations; guidance for FY2026 and FY2027 exceeds prior outlook, creating fresh buying impetus.

Market effects

Sector

Medical device and automation technology sectors may see broader optimism from Novanta's growth.

Regional

U.S. small‑cap tech stocks could benefit from the earnings beat.

Global

Limited to investors focused on niche med‑tech equipment suppliers.

Counterpoint

What could challenge this read

If the acquisition integration costs exceed expectations, the upside could be muted.

Key entities

Company
Novanta Inc.
Medical and advanced technology equipment supplier (NASDAQ: NOVT).
Executive
Matthijs Glastra
Chair and CEO of Novanta.

Read at source ← All news

$NOVTHighAI 8/10

Why is Novanta stock tumbling today?

Novanta (NOVT) shares fell 14.7% after Q3 2026 earnings call, with GAAP operating margin dropping to 4.6% from 11.5% YoY. Adjusted EPS guidance for Q4 was reduced to $0.91–$0.96, below consensus of $1.02. Insider selling and macroeconomic concerns added to the decline, with shares hitting an intraday low of $120.24.

investing.comNov 10

$NOVTHighAI 8/10

Novanta’s (NASDAQ:NOVT) Q3 2026 sales beat estimates but guides down full-year adjusted EPS

Novanta reported Q3 2026 sales of $305M, beating estimates by 1.3%. Adjusted EPS was $1.05, an 8.6% beat. Adjusted EBITDA was $80.34M, a 4.4% beat. Q4 revenue guidance is $309M, in line with estimates. Full-year adjusted EPS guidance was lowered to $3.69. Operating margin declined to 4.6% from 11.5% YoY, while free cash flow margin increased to 10% from 1.7%.

finance.yahoo.comNov 9

$NOVTMedAI 8/10

Novanta earnings beat by $0.11, revenue topped estimates

Novanta (NOVT) reported Q3 EPS of $1.05, beating estimates by $0.11, with revenue at $305M, surpassing expectations of $262.82M. The company provided Q4 and FY 2026 guidance, with EPS and revenue estimates generally in line with or slightly below consensus. NOVT's stock is down 12.72% over the last 3 months but up 40.37% year-over-year.

investing.comNov 9

$NOVTMed

Novanta 3Q 2026: Revenue $305.01M, EPS $0.05 — 10-Q Summary

Novanta reported 3Q 2026 revenue of $305.01M, up 23.1% YoY, but net income fell 81.1% to $2.02M due to higher costs. Automation segment revenue rose 16%, while Medical Solutions grew 30.3%, including $32.9M from Riverpoint Medical acquisition. Gross margins varied across segments.

tradingview.comNov 9

$NOVTHigh

Novanta: Q3 Earnings Snapshot

Novanta Inc. (NOVT) reported Q3 net income of $2M, or 5 cents per share, with adjusted earnings of $1.05 per share. Revenue was $305M. For Q4, it forecasts earnings of 91-96 cents per share and revenue of $306M-$312M. Full-year earnings are expected to be $3.66-$3.71 per share, with revenue of $1.14B.

finance.yahoo.comNov 9

$NOVTHigh